Algorithms for the management of metastatic colorectal cancer: (A) resectable metastatic disease; (B) metastatic disease, first-line; (C) metastatic disease,

Slides:

Advertisements

Similar presentations

FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev

Advertisements

Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent trials settled the question of maintenance versus observation in advanced CRC? Yes Deborah Schrag,

Individualizing Therapy for Gastrointestinal Malignancies 2010 Update

Which biological targeted agent and for whom?

Patterns of Care in Medical Oncology Neoadjuvant and Adjuvant Treatment of Rectal Cancer.

Treatment options depend on the following: – The stage of the cancer – Whether the cancer has recurred – The patient’s general health.

Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer N016966: Efficacy Results  PFS significantly.

Targeting VEGF for the Treatment of Colorectal Cancer Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA.

Dr Francis Daniel, MB. ChB, FFR-RCSI, FRCR. Consultant in Clinical Oncology

Patterns of Care in Medical Oncology Treatment of Metastatic Colon Cancer.

Higher Vitamin D Levels Associated With Improved Survival in Metastatic Colorectal Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.

Power to the Patient With Cancer: Aligning Communication Between Patients and Clinicians This program is supported by an educational grant from Genentech.

CCO Independent Conference Coverage

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

What is the best cytotoxic backbone for biologicals?

Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies A. Vogel, R.D. Hofheinz, S. Kubicka, D. Arnold

Systemic treatment for colorectal cancer

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

Axel Grothey Professor of Oncology Mayo Clinic Rochester

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Fit for treatment Confirmed mCRC Request RAS Yes Liver only disease?

A proposed treatment model for the decision-making process when choosing between cetuximab continuation vs rechallenge. aTypically patients with left-sided,

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

The decision tree with the two alternatives.

Detection rate for EGFR mutations in cfDNA.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

PRISMA study flow diagram

Methods distribution among the three EQAs

Clinical courses of patients.

Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.

Illustration of common sites of pelvic relapse post-radical cystectomy in patients with ≥pT3 tumours, 9 18 stratified by margins status - (L) positive.

Detection rate of EGFR mutations in cfDNA by characteristics

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

Discussion on Abstracts 362, 363, 364, 365, and 366 or…We still have a lot to learn about colorectal cancer Johanna Bendell, MD Director, GI Oncology Research.

Targeted Therapies for Hepatocellular Carcinoma

Awareness of respondents about the availability or development of specialised services for AYA where adult and paediatric cancer specialists work together.

PFS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients (n=34). mPFS, median.

Forest plots for all drugs (OS and PFS HRs combined): excellent versus reduced PS comparison and ECOG PS levels comparison (see online supplementary 1). ECOG.

Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Application of 5-aminolevulinic acid (5-ALA) induced fluorescence during resection of a brain metastasis. Application of 5-aminolevulinic acid (5-ALA)

(A) Progression-free survival in the hormone receptor-negative cohort patients treated with PARPi versus those treated with mono chemotherapy (controls).

1Sunnybrook Health Sciences Centre, University of Toronto, Canada

Proportion of continuous, intermittent, and limited (

Overview of cancer genetics in the SMP1 cohort: lung cancer (A), breast cancer (B), colorectal adenocarcinoma (except mucinous subtype) (C), prostate cancer.

(A) The stratified analysis for DFS because of the uncertain status of HER2, 132 patients could be calculated the recurrence risk score. (A) The stratified.

The 22 study patients: overall survival (first patient enrolled 9 May 2014, last patient enrolled 26 August 2015, censoring date 9 May 2016); primary tumour.

Colorectal Cancer in Older Patients Key Issues

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Three-year DFS rates of T x N subsets of the ACTS-CC trial and IDEA study.19 Annotation: definitions of DFS in ACTS-CC and IDEA were different. Three-year.

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Treatmentalgorithm for metastatic TNBC patients consideringthe incorporation of PARPis and immunotherapy. *Defined as PD-L1 expression on tumour-infiltratingimmune.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Clinical characteristics at diagnosis of brain metastases.

Schema of the exploratory analyses (RAS wild-type population)

(A) Survival curves according to clinical response.

Kaplan-Meier analysis of overall survival in patients receiving panitumumab→VEGFi (PEAK and PRIME) versus bevacizumab→EGFRi (PEAK and 181) in the (A) RAS.

Consort diagram of the study depicting the process of patients’ selection. Consort diagram of the study depicting the process of patients’ selection. A.

Time to progression and overall survival for patients according to four factors (in order, top to bottom): debulking surgery or not, residual disease after.

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

Time to progression and overall survival for patients who had dose-dense chemotherapy, according to two factors (in order, top to bottom): type of dose-dense.

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

Algorithms for the management of metastatic colorectal cancer: (A) resectable metastatic disease; (B) metastatic disease, first-line; (C) metastatic disease, subsequent lines. 5-FU, 5-fluorouracil; Aflib, aflibercept; Bev, bevacizumab; Cape, capecitabine; Cet, cetuximab; CT, chemotherapy; EGFR, epidermal growth factor receptor; FOLFIRI, 5-fluorouracil+lederfolin+irinotecan; FOLFIRI, folinic acid, 5-FU and irinotecan; FOLFOX, folinic acid, 5-FU and oxaliplatin; LV, lederfolin; mut, mutant; PD, progressive disease; PS, performace status; pts, patients; RT, radiotherapy; wt, wild type; XELOX, capecitabine+oxaliplatin. Algorithms for the management of metastatic colorectal cancer: (A) resectable metastatic disease; (B) metastatic disease, first-line; (C) metastatic disease, subsequent lines. 5-FU, 5-fluorouracil; Aflib, aflibercept; Bev, bevacizumab; Cape, capecitabine; Cet, cetuximab; CT, chemotherapy; EGFR, epidermal growth factor receptor; FOLFIRI, 5-fluorouracil+lederfolin+irinotecan; FOLFIRI, folinic acid, 5-FU and irinotecan; FOLFOX, folinic acid, 5-FU and oxaliplatin; LV, lederfolin; mut, mutant; PD, progressive disease; PS, performace status; pts, patients; RT, radiotherapy; wt, wild type; XELOX, capecitabine+oxaliplatin. Lisa Salvatore et al. ESMO Open 2017;2:e000147 Copyright © European Society for Medical Oncology. All rights reserved.